6A3A Stock Chart & Stats
€1.32
€0.08(6.45%)
At close: 4:00 PM EDT
€1.32
€0.08(6.45%)
Day’s Range― - ―
52-Week Range€1.04 - €2.16
Previous CloseN/A
Volume0.00
Average Volume (3M)1.20K
Market Cap
€337.58M
Enterprise Value€505.47
Total Cash (Recent Filing)€229.43M
Total Debt (Recent Filing)€79.96M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding266,155,800
10 Day Avg. Volume0
30 Day Avg. Volume1,203
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)2.97
Price to Sales (P/S)7.01
P/FCF Ratio-1.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.10Price Target Upside438.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.77
Revenue Forecast (FY)€113.41M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue TractionSustained, large YoY product revenue growth reflects early product-market fit and meaningful commercial adoption across centers. Durable revenue generation from AUCATZYL supports scaling economics, improves visibility into mid‑term revenue, and underpins reinvestment and reimbursement negotiations.
Margin Improvement & Scale PlansAchieving a positive gross profit signals that unit economics are moving toward sustainability. Combined with plans to double production while holding staffing, this indicates potential durable margin expansion as fixed costs spread and process optimizations take effect.
Pipeline Breadth And Real‑world EfficacyStrong real‑world outcomes and a diversified clinical timetable (pediatric, MS, lupus nephritis, follow‑ups) materially de‑risks label expansion and broadens addressable markets. Durable benefit: multiple potential revenue streams and longer runway to sustained commercial scale if trials confirm efficacy.
Bears Say
Heavy Cash Burn And Limited RunwayPersistent negative operating cash flow and a runway under two years create a structural financing requirement. Ongoing burn raises dilution risk, forces capital‑raising timing decisions, and can constrain strategic flexibility for R&D, commercialization, or M&A over the medium term.
Sustained Company LossesLarge, persistent operating and net losses indicate the company remains far from company‑level profitability. Even with product margin progress, corporate cost base and SG&A increases for commercialization mean profitability timing and shareholder returns remain uncertain.
Execution & Market Access RiskScaling manufacturing and securing European reimbursement are structural execution challenges. Failure or delay in tech transfer or market access would limit capacity for new indications and international revenue, undermining projected unit economics and long‑term growth.
Autolus Therapeutics News
6A3A FAQ
What was Autolus Therapeutics’s price range in the past 12 months?
Autolus Therapeutics lowest stock price was €1.04 and its highest was €2.16 in the past 12 months.
What is Autolus Therapeutics’s market cap?
Autolus Therapeutics’s market cap is €337.58M.
When is Autolus Therapeutics’s upcoming earnings report date?
Autolus Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 90 days.
How were Autolus Therapeutics’s earnings last quarter?
Currently, no data Available
Is Autolus Therapeutics overvalued?
According to Wall Street analysts Autolus Therapeutics’s price is currently Undervalued.
Does Autolus Therapeutics pay dividends?
Autolus Therapeutics does not currently pay dividends.
What is Autolus Therapeutics’s EPS estimate?
Autolus Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Autolus Therapeutics have?
Autolus Therapeutics has 266,155,800 shares outstanding.
What happened to Autolus Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Autolus Therapeutics?
Currently, no hedge funds are holding shares in DE:6A3A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Autolus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€7.10 (438.08% Upside)
€7.10 (438.08% Upside)
Blogger Sentiment
Bullish
DE:6A3A Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-29.38%
Trailing 12-Months
Company Description
Autolus Therapeutics
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
6A3A Company Deck
6A3A Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflected strong commercial momentum and operational progress: quarterly revenue surged (~191% YoY), the company achieved its first positive gross margin quarter, and production efficiency initiatives target lower per-unit costs and $15M annualized savings in 2027. Real-world data and multiple near- and mid-term clinical readouts underpin a promising pipeline and support expansion into new indications and geographies. Offsetting these positives are continued high net losses, significant cash drawdown (cash runway into Q4 2027), a sizable rise in SG&A to support commercialization, and execution risks related to manufacturing scale-up and European market access. Overall, while financial and execution risks remain, the balance of substantial commercial progress, margin improvement, and clear pipeline milestones leads to a constructive outlook.View all DE:6A3A earnings summaries6A3A Stock 12 Month Forecast
Average Price Target
€7.10
▲(438.08% Upside)
Technical Analysis
Tvardi Therapeutics
―
Larimar Therapeutics
―
Benitec Biopharma
―
Diamedica Therapeutics
―
Contineum Therapeutics, Inc. Class A
―